Vol 7, No 5 (October 01, 2016): Journal of Gastrointestinal Oncology (Genetic Diversity of Gastrointestinal Malignancies and Emerging Targets: A New World Order)

Editorial

Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape
Tanios Bekaii-Saab, Bassel El-Rayes
Journal of Gastrointestinal Oncology  
2016;
7
(5)
:673-674
.
 (01 October 2016) 
PDF Full Text (2653) Open Access Get Permission

Review Article

Clinical applications of liquid biopsies in gastrointestinal oncology
Jason Zhu, John H. Strickler
Journal of Gastrointestinal Oncology  
2016;
7
(5)
:675-686
.
 (01 October 2016) 
PDF Full Text (7855) Open Access Get Permission
RAS and BRAF in metastatic colorectal cancer management
Jun Gong, May Cho, Marwan Fakih
Journal of Gastrointestinal Oncology  
2016;
7
(5)
:687-704
.
 (01 October 2016) 
PDF Full Text (21853) Open Access Get Permission
Beyond RAS and BRAF: a target rich disease that is ripe for picking
Tyler Friedrich, Stephen Leong, Christopher H. Lieu
Journal of Gastrointestinal Oncology  
2016;
7
(5)
:705-712
.
 (01 October 2016) 
PDF Full Text (6222) Open Access Get Permission
Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others
Manojkumar Bupathi, Christina Wu
Journal of Gastrointestinal Oncology  
2016;
7
(5)
:713-720
.
 (01 October 2016) 
PDF Full Text (9927) Open Access Get Permission
Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach
Van Morris, Cathy Eng
Journal of Gastrointestinal Oncology  
2016;
7
(5)
:721-726
.
 (01 October 2016) 
PDF Full Text (4927) Open Access Get Permission
Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?
Namrata Vijayvergia, Steven J. Cohen
Journal of Gastrointestinal Oncology  
2016;
7
(5)
:727-737
.
 (01 October 2016) 
PDF Full Text (6038) Open Access Get Permission
Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?
Min Yuen Teo, Eileen M. O’Reilly
Journal of Gastrointestinal Oncology  
2016;
7
(5)
:738-749
.
 (01 October 2016) 
PDF Full Text (6923) Open Access Get Permission
The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyond
Ciara M. Kelly, Yelena Y. Janjigian
Journal of Gastrointestinal Oncology  
2016;
7
(5)
:750-762
.
 (01 October 2016) 
PDF Full Text (14874) Open Access Get Permission
Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers
Jimmy Hwang
Journal of Gastrointestinal Oncology  
2016;
7
(5)
:763-770
.
 (01 October 2016) 
PDF Full Text (4440) Open Access Get Permission
The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1
Zhaohui Jin, Harry H. Yoon
Journal of Gastrointestinal Oncology  
2016;
7
(5)
:771-788
.
 (01 October 2016) 
PDF Full Text (13876) Open Access Get Permission
The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?
Sumera I Ilyas, Mitesh J. Borad
Journal of Gastrointestinal Oncology  
2016;
7
(5)
:789-796
.
 (01 October 2016) 
PDF Full Text (6937) Open Access Get Permission
Molecular profiling of biliary tract cancer: a target rich disease
Apurva Jain, Milind Javle
Journal of Gastrointestinal Oncology  
2016;
7
(5)
:797-803
.
 (01 October 2016) 
PDF Full Text (12690) Open Access Get Permission
Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?
Michael S. Lee, Bert H. O’Neil
Journal of Gastrointestinal Oncology  
2016;
7
(5)
:804-818
.
 (01 October 2016) 
PDF Full Text (6120) Open Access Get Permission

Disclosure:

The focused issue “Genetic Diversity of Gastrointestinal Malignancies and Emerging Targets: A New World Order” was commissioned by the Editorial office, Journal of Gastrointestinal Oncology without any sponsorship or funding. Tanios Bekaii-Saab and Bassel El-Rayes served as the unpaid Guest Editors for the focused issue.